Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
75%
Ph phase_3
1
25%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Other(1)

Detailed Status

Completed1
Recruiting1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (75.0%)
Phase 31 (25.0%)

Trials by Status

completed125%
recruiting125%
unknown125%
active_not_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

NCT07174427
active_not_recruitingphase_1

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

NCT02869217
completedphase_1

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

NCT03250325
unknownphase_1

Investigator Initiated Phase 1 Study of TBI-1301

NCT02366546

Clinical Trials (4)

Showing 4 of 4 trials
NCT07174427Phase 3

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Recruiting
NCT02869217Phase 1

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Active Not Recruiting
NCT03250325Phase 1

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Completed
NCT02366546Phase 1

Investigator Initiated Phase 1 Study of TBI-1301

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4